SEGMENT REPORTING (Tables)

9 Months Ended

Sep. 30, 2025

Segment Reporting [Abstract]

Schedule of financial information by reportable segments

Financial information by reportable segment is as follows:

	Three Months Ended September 30, 2025
	Generics and Other		Rare Disease and Brands		Corporate and Unallocated		Total
Net Revenues	$	98,688	$	129,125	$	—	$	227,813
Less:
Cost of sales (excluding depreciation and amortization)	53,736		39,653		—		93,389
Research and development	8,472		3,832		—		12,304
Selling, general, and administrative	1,405		43,983		31,268		76,656
Depreciation and amortization	—		—		22,632		22,632
Contingent consideration fair value adjustment	—		—		(14,470)		(14,470)
Loss on disposal of assets	—		—		295		295
Intangible asset impairment charge	—		—		767		767
Operating Income (Loss)	$	35,075	$	41,657	$	(40,492)	$	36,240
Unrealized gain on investment in equity securities	$	—	$	—	$	3,140	$	3,140
Interest expense, net	—		—		(4,727)		(4,727)
Other expense, net	—		—		(853)		(853)
Income (Loss) Before Income Tax Expense	$	35,075	$	41,657	$	(42,932)	$	33,800

	Three Months Ended September 30, 2024
	Generics and Other		Rare Disease and Brands		Corporate and Unallocated		Total
Net Revenues	$	82,711	$	65,621	$	—	$	148,332
Less:
Cost of sales (excluding depreciation and amortization)	42,585		20,490		—		63,075
Research and development	6,123		4,005		—		10,128
Selling, general, and administrative	1,384		35,705		41,986		79,075
Depreciation and amortization	—		—		15,748		15,748
Contingent consideration fair value adjustment	—		—		825		825
Operating (Loss) Income	$	32,619	$	5,421	$	(58,559)	$	(20,519)
Unrealized gain on investment in equity securities	$	—	$	—	$	1,355	$	1,355
Interest expense, net	—		—		(2,331)		(2,331)
Other expense, net	—		—		(2,535)		(2,535)
Loss on extinguishment of debt	—		—		(7,468)		(7,468)
Income (Loss) Before Income Tax Benefit	$	32,619	$	5,421	$	(69,538)	$	(31,498)

	Nine Months Ended September 30, 2025
	Generics and Other		Rare Disease and Brands		Corporate and Unallocated		Total
Net Revenues	$	295,941	$	340,365	$	—	$	636,306
Less:
Cost of sales (excluding depreciation and amortization)	143,468		97,573		—		241,041
Research and development	26,474		12,929		—		39,403
Selling, general, and administrative	4,202		137,610		93,143		234,955
Depreciation and amortization	—		—		68,804		68,804
Contingent consideration fair value adjustment	—		—		(25,285)		(25,285)
Loss on disposal of assets	—		—		295		295
Intangible asset impairment charge	—		—		767		767
Operating Income (Loss)	$	121,797	$	92,253	$	(137,724)	$	76,326
Unrealized gain on investment in equity securities	$	—	$	—	$	2,551	$	2,551
Interest expense, net	—		—		(15,649)		(15,649)
Other income, net	—		—		1,084		1,084
Income (Loss) Before Income Tax Expense	$	121,797	$	92,253	$	(149,738)	$	64,312

	Nine Months Ended September 30, 2024
	Generics and Other		Rare Disease and Brands		Corporate and Unallocated		Total
Net Revenues	$	236,346	$	187,456	$	—	$	423,802
Less:
Cost of sales (excluding depreciation and amortization)	121,399		48,531		—		169,930
Research and development	19,569		8,366		—		27,935
Selling, general, and administrative	3,737		86,720		89,460		179,917
Depreciation and amortization	—		—		45,131		45,131
Contingent consideration fair value adjustment	—		—		1,274		1,274
Gain on sale of building	—		—		(5,347)		(5,347)
Operating Income (Loss)	$	91,641	$	43,839	$	(130,518)	$	4,962
Unrealized gain on investment in equity securities	$	—	$	—	$	8,298	$	8,298
Interest expense, net	—		—		(11,587)		(11,587)
Other expense, net	—		—		(2,655)		(2,655)
Loss on extinguishment of debt	—		—		(7,468)		(7,468)
Income (Loss) Before Income Tax Benefit	$	91,641	$	43,839	$	(143,930)	$	(8,450)